Graft loss risk in renal transplant recipients with metabolic syndrome: Subgroup analyses of the ALERT trial

Journal of Nephrology

Volumn 25, Issue 2, 2012, Pages 245-254

  Soveri, Inga ^a   Abedini, Sadollah ^b   Holdaas, Hallvard ^b   Jardine, Alan ^c   Eriksson, Niclas ^d   Fellström, Bengt ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c General Infirmary   (United Kingdom)

^d UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

Author keywords

Kidney transplantation; Metabolic syndrome; Renal graft loss; Statins

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CREATININE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT RESPONSE;

ADULT; AGED; CREATININE; DOUBLE-BLIND METHOD; FATTY ACIDS, MONOUNSATURATED; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNE TOLERANCE; INDOLES; KIDNEY TRANSPLANTATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84863326685     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2011.8450     Document Type: Article

References (32)

1. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605-612.
2. Kreis HA, Ponticelli C. Causes of late renal allograft loss: chronic allograft dysfunction, death, and other factors. Transplantation. 2001;71(Suppl):SS5-SS9.
3. Roodnat JI, Mulder PG, Zietse R, et al. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation. 2000;69:1704-1710.
4. Tutone VK, Mark PB, Stewart GA, et al. Hypertension, antihypertensive agents and outcomes following renal transplantation. Clin Transplant. 2005;19:181-192.
5. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178-185.
6. Fellström B, Holdaas H, Jardine AG, et al; Assessment of Lescol in Renal Transplantation Study Investigators. Risk factors for reaching renal endpoints in the Assessment of Lescol in Renal Transplantation (ALERT) trial. Transplantation. 2005;79:205-212.
7. Gore JL, Pham PT, Danovitch GM, et al. Obesity and outcome following renal transplantation. Am J Transplant. 2006;6:357-363.
8. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070-1077.
9. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
10. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K; DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164:1066-1076.
11. Ekstrand AV, Eriksson JG, Grönhagen-Riska C, Ahonen PJ, Groop LC. Insulin resistance and insulin deficiency in the pathogenesis of posttransplantation diabetes in man. Transplantation. 1992;53:563-569.
12. Courivaud C, Kazory A, Simula-Faivre D, Chalopin JM, Ducloux D. Metabolic syndrome and atherosclerotic events in renal transplant recipients. Transplantation. 2007;83:1577-1581.
13. Faenza A, Fuga G, Nardo B, et al. Metabolic syndrome after kidney transplantation. Transplant Proc. 2007;39:1843-1846.
14. Soveri I, Abedini S, Holdaas H, Jardine A, Eriksson N, Fellström B. Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clin Transplant. 2009;23:914-920.
15. Chen J, Muntner P, Hamm LL, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol. 2003;14:469-477.
16. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134-2140.
17. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J Am Soc Nephrol. 2004;15:2775-2791.
18. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:550-562.
19. de Vries AP, Bakker SJ, van Son WJ, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant. 2004;4:1675-1683.
20. Porrini E, Delgado P, Bigo C, et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis. 2006;48:134-142.
21. Ducloux D, Kazory A, Simula-Faivre D, Chalopin JM. Oneyear post-transplant weight gain is a risk factor for graft loss. Am J Transplant. 2005;5:2922-2928.
22. Zhang W, Liu M, Wu Y, et al. Protective effects of atorvastatin on chronic allograft nephropathy in rats. J Surg Res. 2007;143:428-436.
23. Holdaas H, Fellström B, Holme I, et al; ALERT Study Group. Assessment of Lescol in Renal Transplantation. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. J Cardiovasc Risk. 2001;8:63-71.
24. Holdaas H, Fellström B, Jardine AG, et al; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361:2024-2031.
25. Holdaas H, Fellström B, Cole E, et al; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Longterm cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5:2929-2936.
26. Meigs JB, Wilson PW, Nathan DM, D'Agostino RB Sr, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes. 2003;52:2160-2167.
27. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
28. Fellström B, Holdaas H, Jardine AG, et al; Assessment of Lescol in Renal Transplantation Study Investigators. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int. 2004;66: 1549-1555.
29. Chitalia N, Raja RB, Bhandara T, et al. Serum adiponectin and cardiovascular risk in chronic kidney disease and kidney transplantation. J Nephrol. 2010;23:77-84.
30. Armstrong KA, Campbell SB, Hawley CM, Nicol DL, Johnson DW, Isbel NM. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant. 2005;5:2710-2718.
31. Fellström B, Abedini S, Holdaas H, Jardine AG, Staffler B, Gimpelewicz C; Assessment of Lescol in Renal Transplantation (ALERT) study group. No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clin Transplant. 2006;20:732-739.
32. Fellström B. Risk factors for and management of posttransplantation cardiovascular disease. BioDrugs. 2001;15: 261-278.